A board-certified doctor will then review your information to determine if you are a candidate for treatment and, if so, will issue a prescription for Sildenafil Arousal Cream. Once your prescription is issued, there’s a 24-hour review period before the pharmacy begins processing your order. The pharmacy typically prepares your medication within 1–3 business days, followed by shipping, which takes another 1–3 business days. On average, most patients receive their Sildenafil Arousal Cream within about 5 business days.
5. Tips
Of participants, 99 and 94, respectively, were in the intention-to-treat (ITT) analysis and 90 and 84, respectively, completed all study visits.1 When measuring outcomes based on the SFQ28 Arousal Sensation domain, increased efficacy was reported for the sildenafil cream group vs the placebo cream group. Your Sildenafil Arousal Cream is delivered directly to your door. Standard shipping is free on all prescriptions. If you need your medication sooner, expedited options are available at checkout, including USPS Priority (2–3 business days) or FedEx Overnight for an additional fee. While Winona is currently unable to bill insurance companies directly, you can use your HSA (Health Savings Account) or FSA (Flexible Spending Account) card to pay for your Sildenafil Arousal Cream at checkout. You’ll also have access to receipts and documentation that you can use to submit and file a claim with your insurance provider for possible reimbursement. The active ingredients in your Sildenafil Arousal Cream, sildenafil and pentoxifylline, are FDA approved. The final medication itself is prepared for you by a state-licensed compounding pharmacy that follows strict quality standards. Winona’s Sildenafil Arousal Cream is only available in one standard dose. Your Winona prescription includes unlimited, 24/7 messaging with your board-certified doctor.
| Aspect | Description | Typical Dosage | Onset of Action |
|---|---|---|---|
| Pharmacology | PDE5 inhibitor originally for male ED | 25-100 mg | 30-60 minutes |
| Approved Use | Not officially approved for women, experimental use | N/A | N/A |
| Common Side Effects | Headache, flushing, nasal congestion | N/A | N/A |
| Contraindications | Nitrates, certain heart conditions | N/A | N/A |
You can ask questions about your Sildenafil Arousal Cream, discuss your symptoms, or explore Winona’s other treatments at any time through the secure Patient Portal. When you need more Sildenafil Arousal Cream, simply request a reorder through your Patient Portal, and the Patient Care Team will arrange shipment. We evaluated the efficacy and safety of sildenafil citrate in spontaneously or surgically postmenopausal women with female sexual arousal disorder (FSAD). Sildenafil (a 50 mg dose adjustable to 100 or 25 mg) was evaluated in a 12-week, double-blind, placebo controlled study in 202 postmenopausal women with FSAD who had protocol specified estradiol and free testosterone concentrations, and/or were receiving estrogen and/or androgen replacement therapy. Patients were excluded if emotional, relationship or historical abuse issues contributed significantly to sexual dysfunction. Primary end points were questions 2 (increased genital sensation during intercourse or stimulation) and 4 (increased satisfaction with intercourse and/or foreplay) from the Female Intervention Efficacy Index (FIEI). Secondary end points sildenafil 20 mg tablets were the remaining questions from this index, the Sexual Function Questionnaire and sexual activity event log questions. Significant improvements in FIEI questions 2 (p = 0.017) and 4 (p = 0.015) were noted with sildenafil compared with placebo. For women with FSAD without concomitant hypoactive sexual desire disorder (HSDD) sildenafil was associated with significantly greater improvement in 5 of 6 FIEI items compared with placebo (p <0.02).
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 50mg | 270 + 8 Pills | 198.48€ 189.03€ | |
| Kamagra Soft Tabs | 100mg | 120 + 6 Pills | 311.78€ 296.93€ | |
| Viagra Generic | 25mg | 180 + 6 Pills | 154.93€ 147.55€ | |
| Viagra Generic | 100mg | 90 + 6 Pills | 129.02€ 122.88€ | |
| Viagra Generic | 200mg | 60 + 4 Pills | 125.19€ 119.23€ | |
| Viagra Generic | 50mg | 180 + 8 Pills | 158.82€ 151.26€ | |
| Viagra Generic | 200mg | 10 Pills | 40.96€ 39.01€ | |
| Viagra Generic | 100mg | 180 + 8 Pills | 199.37€ 189.88€ | |
| Kamagra Oral Jelly | 100mg | 63 + 7 Sachets | 224.18€ 213.50€ | |
| Kamagra Polo | 100mg | 180 + 8 Pills | 446.52€ 425.26€ | |
| Kamagra Soft Tabs | 100mg | 12 Pills | 57.55€ 54.81€ | |
| Kamagra Oral Jelly | 100mg | 30 + 5 Sachets | 136.20€ 129.71€ | |
| Viagra Generic | 150mg | 10 Pills | 36.73€ 34.98€ |
No significant improvements were shown for women with concomitant HSDD. Most adverse events were mild to moderate with headache, flushing, rhinitis, nausea and visual symptoms reported most frequently.
- Sildenafil is primarily approved for erectile dysfunction in men.
- Some studies explore its potential to treat female arousal disorder.
- Its use for women remains off-label in many regions.
- Long-term safety data for women is limited.
Sildenafil was effective and well tolerated in postmenopausal women with FSAD without concomitant HSDD or contributory emotional, relationship or historical abuse issues. All patients had protocol specified estradiol and free testosterone concentrations or were receiving estrogen and/or androgen replacement therapy. 1 : Report of the International Consensus Development Conference on Female Sexual Dysfunction: definitions and classifications. 2 : Female sexual arousal disorder: new insights. 5 : Development of human and rabbit vaginal smooth muscle cell cultures: effects of vasoactive agents on intracellular levels of cyclic nucleotides. 7 : Sildenafil, a novel effective oral therapy for male erectile dysfunction. 8 : Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder.
- Research shows mixed results on sildenafil's benefits for women.
- It may improve sexual satisfaction in some women.
- Not recommended for women with cardiovascular conditions.
- Using sildenafil without medical advice is risky.
9 : Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Galpha(i). 10 : Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes. 11 Guay, A., Munarriz, R., Jacobson, M.A., Talakoub, L., Goldstein, I., Traish, A.
2. Upsides
From the Department of Urology, University of California-Los Angeles Medical Center, Los Angeles, California, Departments of Obstetrics and Gynecology, and Psychiatry, Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, Illinois, and Pfizer Global Research and Development, Groton, Connecticut, and Sandwich, United Kingdom Topical sildenafil cream is effective for improving outcomes in women with female sexual arousal disorder, according to a recent study published in Obstetrics & Gynecology.1 Topical sildenafil cream has shown promising results in improving sexual arousal outcomes for women with female sexual arousal disorder. The study, published in Obstetrics & Gynecology, found that women using sildenafil cream experienced significant improvements in sexual arousal sensation compared to those using a placebo. Phase 1 and phase 2 studies indicated that sildenafil cream is safe, well-tolerated, and sildenafil 100mg blue pill effective for treating female sexual arousal disorder. Significant improvements were observed in the SFQ28 Desire domain scores at week 8, especially in women with only female sexual desire disorder. Researchers suggest future studies should include a more diverse population by removing restrictions on enrolling sexual partners, to better evaluate the cream's efficacy.
Female Sexual Dysfunction—Medical and Psychological Treatments, Committee 14
Female sexual arousal disorder, presenting in approximately 20% of US women, refers to the inability to attain or maintain sexual arousal and often leads to distress and interpersonal difficulty. Currently, no pharmacologic treatments have received FDA approval for managing this condition in the United States. While oral sildenafil has shown little efficacy compared to placebo and high rates of side effects, topical sildenafil cream 3.6% (sildenafil cream) is another method of managing female sexual arousal disorder symptoms. Topical administration of sildenafil may also reduce side effects and provide a more immediate biological efficacy response. Sildenafil cream is an investigational proprietary topical formulation designed for the treatment of female sexual arousal disorder.2 Phase 1 and phase 2 studies have indicated safety, tolerance, and efficacy from sildenafil cream use.
Addyi (filbanserin)
Investigators conducted a clinical trial to evaluate the safety and efficacy of sildenafil cream among women with female sexual arousal disorder.1 Participants included healthy premenopausal women aged at least 18 years and their sexual partners. Female sexual arousal disorder outcomes were assessed using the Arousal Sensation domain of the Sexual Function Questionnaire (SFQ38) and question 14 of the Female Sexual Distress Scale—Desire, Arousal, Orgasm (FSDS-DAO). Changes from baseline to week 12 were measured.1 A female sexual arousal disorder diagnosis and status as the woman’s primary sexual dysfunction concern were determined through a 1-on-1 clinical interview. Participants underwent a no-drug run-in period for 28 days, with eligibility determined by compliance with recorded sexual and adverse events. Following the no-drug run-in period, eligible participants were randomized 1:1 to receive sildenafil cream or placebo cream for a 12-week double-blind period. et-al: Androgen values in premenopausal women without sexual dysfunction.
- Sildenafil is being studied for female sexual dysfunction.
- It may improve blood flow to vaginal tissues.
- Not officially approved for women in many countries.
- Side effects can include headaches and flushing.
Presented at International Society for the Study of Women's Sexual Health, Vancouver, British Columbia, Canada, October 10–13, 2002 Google Scholar 13 : Development of a sexual function questionnaire for clinical trials of female sexual dysfunction. J Womens Health Gend Based Med2002; 11: 277. 14 : The use of the Female Intervention Efficacy Index (FIEI) as an immediate outcome measure of medical intervention to treat female sexual dysfunction. 15 : Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder.
| Aspect | Description | Considerations |
|---|---|---|
| Expectation Management | Enhancing sexual satisfaction through expectations | Important to set realistic goals |
| Placebo Effect | Some improvements due to psychological factors | Not solely pharmacological |
| Partner Support | Facilitates better outcomes | Communication is key |
| Psychological Counseling | May benefit women with sexual dysfunction | Can optimize use and outcomes |
J Womens Health Gend Based Med2002; 11: 367. 16 : Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. 17 : Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. 18 : Effects of ovariectomy and estrogen and androgen treatment on sildenafil-mediated changes in female genital blood flow and vaginal lubrication in the animal model. 19 : The role of androgen in the maintenance of sexual functioning in oophorectomized women. 20 : Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality.
Serious side effects (seek immediate help)
8 : Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder. 9 : Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Galpha(i). 10 : Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes. 11 Guay, A., Munarriz, R., Jacobson, M.A., Talakoub, L., Goldstein, I., Traish, A. et-al: Androgen values in premenopausal women without sexual dysfunction.
Key takeaways
Presented at International Society for the Study of Women's Sexual Health, Vancouver, British Columbia, Canada, October 10–13, 2002 Google Scholar 13 : Development of a sexual function questionnaire for clinical trials of female sexual dysfunction. J Womens Health Gend Based Med2002; 11: 277. 14 : The use of the Female Intervention Efficacy Index (FIEI) as an immediate outcome measure of medical intervention to treat female sexual dysfunction. 15 : Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med2002; 11: 367.
Authors and Affiliations
16 : Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. 17 : Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. 18 : Effects of ovariectomy and estrogen and androgen treatment on sildenafil-mediated changes in female genital blood flow and vaginal lubrication in the animal model. 19 : The role of androgen in the maintenance of sexual functioning in oophorectomized women. 20 : Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. From the Department of Urology, University of California-Los Angeles Medical Center, Los Angeles, California, Departments of Obstetrics and Gynecology, and Psychiatry, Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, Illinois, and Pfizer Global Research and Development, Groton, Connecticut, and Sandwich, United Kingdom Topical sildenafil cream is effective for improving outcomes in women with female sexual arousal disorder, according to a recent study published in Obstetrics & Gynecology.1 Topical sildenafil cream has shown promising results in improving sexual arousal outcomes for women with female sexual arousal disorder. The study, published in Obstetrics & Gynecology, found that women using sildenafil cream experienced significant improvements in sexual arousal sensation compared to those using a placebo. Phase 1 and phase 2 studies indicated that sildenafil cream is safe, well-tolerated, and sildenafil 100mg blue pill effective for treating female sexual arousal disorder.
Are there other uses for this medicine?
A board-certified doctor will then review your information to determine if you are a candidate for treatment and, if so, will issue a prescription for Sildenafil Arousal Cream. Once your prescription is issued, there’s a 24-hour review period before the pharmacy begins processing your order. The pharmacy typically prepares your medication within 1–3 business days, followed by shipping, which takes another 1–3 business days. On average, most patients receive their Sildenafil Arousal Cream within about 5 business days. Your Sildenafil Arousal Cream is delivered directly to your door.
Future Directions
Standard shipping is free on all prescriptions. If you need your medication sooner, expedited options are available at checkout, including USPS Priority (2–3 business days) or FedEx Overnight for an additional fee. While Winona is currently unable to bill insurance companies directly, you can use your HSA (Health Savings Account) or FSA (Flexible Spending Account) card to pay for your Sildenafil Arousal Cream at checkout. You’ll also have access to receipts and documentation that you can use to submit and file a claim with your insurance provider for possible reimbursement. The active ingredients in your Sildenafil Arousal Cream, sildenafil and pentoxifylline, are FDA approved.
Recent advances in female sexual dysfunction
The final medication itself is prepared for you by a state-licensed compounding pharmacy that follows strict quality standards. Winona’s Sildenafil Arousal Cream is only available in one standard dose. Your Winona prescription includes unlimited, 24/7 messaging with your board-certified doctor. You can ask questions about your Sildenafil Arousal Cream, discuss your symptoms, or explore Winona’s other treatments at any time through the secure Patient Portal. When you need more Sildenafil Arousal Cream, simply request a reorder through your Patient Portal, and the Patient Care Team will arrange shipment. Significant improvements were observed in the SFQ28 Desire domain scores at week 8, especially in women with only female sexual desire disorder.
What Would Viagra Do to a Woman?
Baseline scores included responses and electronic diary data at the end of the run-in period, and double-blind visits occurred at weeks 4, 8, and 12. During double-blind visits, patients completed 1-month recall SFQ28 and FSDS-DAO surveys. Within 24 hours of a sexual event, participants recorded data in an electronic diary. Participants’ response to the question “Did you consider sexual activity satisfactory for you?” in the electronic diary after a sexual event was the secondary outcome of the analysis, measured as the changes in the number and proportion of satisfying events from baseline to week 12. There were 200 participants included in the final analysis, 101 of whom received sildenafil cream and 99 placebo cream. Researchers suggest future studies should include a more diverse population by removing restrictions on enrolling sexual partners, to better evaluate the cream's efficacy. Female sexual arousal disorder, presenting in approximately 20% of US women, refers to the inability to attain or maintain sexual arousal and often leads to distress and interpersonal difficulty.
- Sildenafil is not a universal solution for female sexual desire disorders.
- Monitored clinical trials are ongoing to assess safety for women.
- Self-medicating with sildenafil can lead to adverse effects.
- It is essential to get a comprehensive diagnosis before use.
Currently, no pharmacologic treatments have received FDA approval for managing this condition in the United States. While oral sildenafil has shown little efficacy compared to placebo and high rates of side effects, topical sildenafil cream 3.6% (sildenafil cream) is another method of managing female sexual arousal disorder symptoms. Topical administration of sildenafil may also reduce side effects and provide a more immediate biological efficacy response. Sildenafil cream is an investigational proprietary topical formulation designed for the treatment of female sexual arousal disorder.2 Phase 1 and phase 2 studies have indicated safety, tolerance, and efficacy from sildenafil cream use. Investigators conducted a clinical trial to evaluate the safety and efficacy of sildenafil cream among women with female sexual arousal disorder.1 Participants included healthy premenopausal women aged at least 18 years and their sexual partners. Female sexual arousal disorder outcomes were assessed using the Arousal Sensation domain of the Sexual Function Questionnaire (SFQ38) and question 14 of the Female Sexual Distress Scale—Desire, Arousal, Orgasm (FSDS-DAO). Changes from baseline to week 12 were measured.1 A female sexual arousal disorder diagnosis and status as the woman’s primary sexual dysfunction concern were determined through a 1-on-1 clinical interview. Participants underwent a no-drug run-in period for 28 days, with eligibility determined by compliance with recorded sexual and adverse events. Following the no-drug run-in period, eligible participants were randomized 1:1 to receive sildenafil cream or placebo cream for a 12-week double-blind period. Baseline scores included responses and electronic diary data at the end of the run-in period, and double-blind visits occurred at weeks 4, 8, and 12. During double-blind visits, patients completed 1-month recall SFQ28 and FSDS-DAO surveys. Within 24 hours of a sexual event, participants recorded data in an electronic diary.
About this article
Participants’ response to the question “Did you consider sexual activity satisfactory for you?” in the electronic diary after a sexual event was the secondary outcome of the analysis, measured as the changes in the number and proportion of satisfying events from baseline to week 12. There were 200 participants included in the final analysis, 101 of whom received sildenafil cream and 99 placebo cream.
How It Works
We evaluated the efficacy and safety of sildenafil citrate in spontaneously or surgically postmenopausal women with female sexual arousal disorder (FSAD). Sildenafil (a 50 mg dose adjustable to 100 or 25 mg) was evaluated in a 12-week, double-blind, placebo controlled study in 202 postmenopausal women with FSAD who had protocol specified estradiol and free testosterone concentrations, and/or were receiving estrogen and/or androgen replacement therapy. Patients were excluded if emotional, relationship or historical abuse issues contributed significantly to sexual dysfunction. Primary end points were questions 2 (increased genital sensation during intercourse or stimulation) and 4 (increased satisfaction with intercourse and/or foreplay) from the Female Intervention Efficacy Index (FIEI). Secondary end points sildenafil 20 mg tablets were the remaining questions from this index, the Sexual Function Questionnaire and sexual activity event log questions.
Vyleesi (Bremalontide)
Significant improvements in FIEI questions 2 (p = 0.017) and 4 (p = 0.015) were noted with sildenafil compared with placebo. For women with FSAD without concomitant hypoactive sexual desire disorder (HSDD) sildenafil was associated with significantly greater improvement in 5 of 6 FIEI items compared with placebo (p <0.02). No significant improvements were shown for women with concomitant HSDD. Most adverse events were mild to moderate with headache, flushing, rhinitis, nausea and visual symptoms reported most frequently. Sildenafil was effective and well tolerated in postmenopausal women with FSAD without concomitant HSDD or contributory emotional, relationship or historical abuse issues.
Effects on sexual dysfunction
All patients had protocol specified estradiol and free testosterone concentrations or were receiving estrogen and/or androgen replacement therapy. 1 : Report of the International Consensus Development Conference on Female Sexual Dysfunction: definitions and classifications. 2 : Female sexual arousal disorder: new insights. 5 : Development of human and rabbit vaginal smooth muscle cell cultures: effects of vasoactive agents on intracellular levels of cyclic nucleotides. 7 : Sildenafil, a novel effective oral therapy for male erectile dysfunction. Of participants, 99 and 94, respectively, were in the intention-to-treat (ITT) analysis and 90 and 84, respectively, completed all study visits.1 When measuring outcomes based on the SFQ28 Arousal Sensation domain, increased efficacy was reported for the sildenafil cream group vs the placebo cream group.